VX-548
Phase 2Small molecule
Vertex PharmaceuticalsVX-548 is one of 24 small molecule programs targeting Radiculopathy. It is currently in Phase 2.
1
Indications
11
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
38 competitors in Radiculopathy
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Advil
KKenvue Brands
Approved
Trental
VValidus Pharmaceuticals
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Marcaine
IInnocoll
Approved
Kenalog
BBassett Healthcare
Approved
Standard Medical Care
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Approved
Voltaren
CCerimon Pharmaceuticals
Phase 3
Medrol
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tics2 trials
Efficacy and Safety2 trials
Moderate Hepatic Impairment1 trial
4 more indications
Radiculopathy1 trial
Renal Impairment1 trial
Drug Interactions1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VX-548. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company